Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells $56,947.77 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Janux Therapeutics Trading Down 2.9%

Shares of JANX opened at $13.36 on Friday. The company has a market capitalization of $814.69 million, a PE ratio of -7.26 and a beta of 2.53. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34. The stock’s 50-day moving average price is $14.50 and its two-hundred day moving average price is $15.56.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million. Equities research analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Janux Therapeutics by 8.6% in the 1st quarter. Bank of America Corp DE now owns 801,646 shares of the company’s stock worth $11,143,000 after acquiring an additional 63,316 shares in the last quarter. Irenic Capital Management LP bought a new position in shares of Janux Therapeutics in the 1st quarter worth about $10,645,000. ADAR1 Capital Management LLC raised its position in shares of Janux Therapeutics by 21.6% in the 1st quarter. ADAR1 Capital Management LLC now owns 298,546 shares of the company’s stock worth $4,150,000 after acquiring an additional 53,094 shares in the last quarter. Rock Springs Capital Management LP raised its position in shares of Janux Therapeutics by 2.3% in the 1st quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock worth $5,101,000 after acquiring an additional 8,211 shares in the last quarter. Finally, Quantinno Capital Management LP raised its position in shares of Janux Therapeutics by 7.6% in the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after acquiring an additional 1,846 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Evercore set a $22.00 target price on Janux Therapeutics in a report on Monday, May 11th. JonesTrading cut their target price on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Cantor Fitzgerald cut their target price on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Wedbush cut their target price on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Finally, Barclays lowered Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.85.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.